Analysis of the Use of Chinese Patent Medicines for Cardiovascular and Cerebrovascular Diseases in a Hospital from 2021 to 2023
Objective:To explore the use of Chinese medicines in cardiovascular and cerebrovascular diseases of a hospital from 2021 to 2023.Methods:The consumption sum,quantity and DDDs of cardiovascular and cerebrovascular Chinese patent medicines in our hospital from 2021 to 2023 were statistically analyzed,and the rational use of drugs was reviewed.Results:Among the 156 kinds of Chinese patent medicines in the hospital,there were 23 kinds of Chinese patent medicines for cardiovascular and cerebrovascular diseases,accounting for 14.74%.Four kinds of Chinese patent medicines ranked in the top 5 in DDDs for three consecutive years were Danshen Injection,Ginkgo Leaf Tablets,Shexiang Baoxin Pills and Wenxin Granules.The survey results of package inserts showed that 13.04%of the Chinese patent medicines were not labeled with clear adverse reactions and contraindications.The main problems in the prescription of Chinese patent medicine were non-standard prescriptions.The most common was the gastrointestinal system adverse reactions.Conclusion:The clinical application of Chinese patent medicine for cardiovascular and cerebrovascular diseases in our hospital is relatively reasonable,but there are still unreasonable conditions.It is suggested to strengthen the clinical application management of Chinese patent medicine for cardiovascular and cerebrovascular diseases.
Chinese medicinesCardiovascular and cerebrovascular diseasesRational therapy